Navigation Links
Cancer scientists link ‘oncometabolite’ to onset of acute myeloid leukemia
Date:7/4/2012

(TORONTO, July 4, 2012) A team of international scientists led by principal investigator Dr. Tak Mak at the Princess Margaret Cancer Centre, University Health Network, has identified a causative link between the product of a mutated metabolic enzyme and the onset of acute myeloid leukemia (AML), one of the most common types of leukemia in adults.

Called an "oncometabolite" for its role in cancer metabolism, the metabolite2-hydroxyglutarate (2HG) is a by-product of a gene mutation of an enzyme known as isocitrate dehydrogenase (IDH).

Says Dr. Tak Mak of the findings published today in Nature: "For the first time, we have demonstrated how a metabolite can cause cancer. This sets the stage for developing inhibitors to block the mutation and prevent the production of this disease-initiating enzyme." The research team included scientists at Weill Cornell Medical College, New York City, and Agios Pharmaceuticals, Cambridge, Massachusetts.

Dr. Mak, Director, The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, is an internationally acclaimed immunologist renowned for his 1984 discovery of cloning the human T-cell receptor. He is also Professor, University of Toronto, in the Departments of Medical Biophysics and Immunology.

The connection between cancer and metabolism has fascinated scientists at Agios and Dr. Mak, who were the first to identify the oncometabolite in research published in Nature (2009) and The Journal of Experimental Medicine (2010). The IDH gene mutation was initially discovered in brain cancers in 2008 by American scientists at Johns Hopkins in Baltimore and subsequently also linked to leukemia.

In the lab, Dr. Mak's team genetically engineered a mouse model with the mutation in its blood system to mimic human AML. They discovered that the gene mutation launches the perfect storm for the oncometabolite to trigger the blood system to increase the stem cells p
'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1 2

Related biology news :

1. The genomics symposium to boost the further development of cancer research
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. Regulation of telomerase in stem cells and cancer cells
4. 5th Latin American Conference on Lung Cancer
5. Husband-wife team set out to improve breast cancer exams
6. Double the pain: RUB biologists find the cause of pain in the treatment of fair skin cancer
7. A new indicator for breast cancer relapse identified
8. UCLA scientists discover how key enzyme involved in aging, cancer assembles
9. Researchers identify need to sample multiple tumor zones in breast cancer
10. Groundbreaking discovery of the cellular origin of cervical cancer
11. UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... sorghum , Trials have begun in Kansas on a ... many plastics, drugs, solvents and food additives. Developed at ... of the bacteria E. coli that metabolizes glucose and ... make key chemical intermediates like succinate is a high ...
... and nearsightedness, too.Working with an Amish-Mennonite family tree, Johns ... what appears to be the first human gene mutation ... nanophthalmos, Greek for "dwarf eye," is a rare, potentially ... called MFRP that helps control eye growth and regulates ...
... the number of living species on earth range from ... million species have been classified and described. Estimating historical ... daunting task. , One tool ecologists - but not ... of existing biological diversity is a long-established rule of ...
Cached Biology News:Bacteria are key to 'green' plastics, drugs 2Bacteria are key to 'green' plastics, drugs 3Scientists focus on 'dwarf eye' 2Scientists focus on 'dwarf eye' 3Space matters: Estimating species diversity in the fossil record 2
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... 2015 Despite recent market ... optimism in biotech,s forecast is the recent run ... advancements.  Active biotechnology & healthcare companies with recent ... PBIO), Sequenom, Inc. (NASDAQ: SQNM ), Sarepta ... Corp. (NASDAQ: RPTP ) and EnteroMedics Inc. ...
(Date:8/25/2015)... SHANGHAI , Aug. 25, 2015   WuXi ... open-access R&D capability and technology platform company serving the ... Holdings Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: ... Hong Kong with 20 years of operations ... the two companies have signed an agreement whereby WuXi,s ...
(Date:8/25/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, ... the company as Chief Operating Officer. Winham, who brings more ... experience, will report directly to HLI,s CEO, J. Craig ... as COO, Winham will be responsible for managing all HLI ... facility operations. HLI currently has three locations in ...
Breaking Biology Technology:Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2
... , May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... orphan medicinal product designation from the Committee for Orphan ... its compound AEZS-108 for the treatment of ovarian cancer. ...
... Biotech Group ( USA ), Inc. (the,"Company" or "Tiens", NYSE AMEX: TBV ), http://www.tiens-bio.com ... , , ... to $18.2,million for the first quarter of 2009. , ... Net income for the first quarter of 2010 was $3.6 million , or $0.05 ...
... N.Y. May 16 Astellas Pharma Inc. (TSE: ... OSIP ), a biotechnology company primarily focused on the discovery, development ... diabetes and obesity, today announced that they have entered into a ... , , ...
Cached Biology Technology:Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Tiens Biotech Group (USA) Reports First Quarter Results 2Tiens Biotech Group (USA) Reports First Quarter Results 3Tiens Biotech Group (USA) Reports First Quarter Results 4Tiens Biotech Group (USA) Reports First Quarter Results 5Tiens Biotech Group (USA) Reports First Quarter Results 6Tiens Biotech Group (USA) Reports First Quarter Results 7Tiens Biotech Group (USA) Reports First Quarter Results 8Tiens Biotech Group (USA) Reports First Quarter Results 9Tiens Biotech Group (USA) Reports First Quarter Results 10Tiens Biotech Group (USA) Reports First Quarter Results 11Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 2Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 3Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 4Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 6
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 30 isolations. The kit provides a ... apoptotic cells from normal c lture using ... is a Ca2+-dependent phospholipid binding protein with ... Cell Isolation Kit provides a simple and ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: